SCHEMBL24505301

SCHEMBL24505301

OC(O)c1cccc(-c2noc(-c3cccc(OC(F)(F)F)c3)n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.60
GRM5 P41594 1/20 0.60
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
TP53 P04637 3/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 4/20 0.45
NR1H4 Q96RI1 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28243415 0.81 NR1H4 (0.66) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL60580 0.81 GRM5 (0.63) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL66433 0.77 NPC1 (0.64) GRM5NPC1RAB9ASMN1; SMN2TP53
SCHEMBL16481833 0.76 L3MBTL1 (0.64) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL18950847 0.76 NPC1 (0.69) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL13416504 0.75 S1PR1 (1.00) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL4187017 0.75 GRM5 (1.00) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL22039251 0.74 S1PR1 (0.57) S1PR1GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL18950875 0.74 NPC1 (0.67) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL1114407 0.73 S1PR1 (0.51) S1PR1GRM5NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889142-B1 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE PTC THERAPEUTICS INC (US) 2022-06-15 EP disclosed